Overweight Clinical Trial
— VitDmetOfficial title:
Randomized Controlled Trial of Vitamin D Supplementation on Glucose Metabolism in Subjects With Components of the Metabolic Syndrome
Verified date | March 2013 |
Source | University of Eastern Finland |
Contact | n/a |
Is FDA regulated | No |
Health authority | Finland: Ethics Committee |
Study type | Interventional |
Vitamin D deficiency is widespread throughout the world, and the deficiency has been
associated with several chronic diseases, such as cardiovascular diseases and diabetes. In
Nordic countries, like in Finland, there is a particular variation in vitamin D status, and
during wintertime, when there is no exposure to ultraviolet-B light from the sun, serum
concentrations of vitamin D decrease substantially. In Finland, some 40% of middle-aged men
and one third of women also have some degree of impairment of glucose metabolism.
The purpose of this trial is to investigate the effects of two different daily doses of
vitamin D on glucose metabolism in men 60 years of age or older and who are vitamin D
deficient, have a high body mass index and at least two characteristics of cardio-metabolic
syndrome.
Altogether 102 subjects with low serum calcidiol (<60 nmol/L) will be recruited and
randomized to one of the three groups: 1) 40 µg/d vitamin D3, 2) 80 µg/d vitamin D3 or 3)
placebo. The supplementation period will last for 6 months from September 2011 to March
2012.
The main hypotheses of the trial are: (1.) Vitamin D supplementation will improve glucose
and insulin metabolism in people with a low baseline vitamin D status, in a dose-dependent
manner. (2.) Vitamin D supplementation will have an effect on the expression of genes
involved in glucose and insulin metabolism and inflammation. (3.) Vitamin D supplementation
will have an effect on epigenetic changes in key genes participating in vitamin D
metabolism.
Status | Completed |
Enrollment | 73 |
Est. completion date | May 2012 |
Est. primary completion date | May 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - Age 60 years or older - Serum calcidiol <75 nmol/L - Body mass index 25-35 kg/m2 - Impaired fasting glucose or impaired glucose tolerance (fasting glucose 5.6-7.0 mmol/L or 2h oral glucose tolerance test glucose 7.8-11.0 mmol/L) Exclusion Criteria: - Any chronic disease and condition, which may hamper to follow the intervention protocol (such as alcohol abuse) - Any chronic disease or therapy which may mask or interact with the investigated effects (such as diabetes or systemic corticosteroid therapy) - Any disease or state that raises a vitamin D related safety concern (such as chronic liver, thyroid or kidney disease, hypercalcemia, sarcoidosis or other granulomatous diseases such as active chronic tuberculosis or Wegener's granulomatosis) - Use of supplements yielding vitamin D over 20 µg/d and unwillingness to discontinue the use. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Finland | University of Eastern Finland, Kuopio Campus | Kuopio |
Lead Sponsor | Collaborator |
---|---|
University of Eastern Finland | Academy of Finland, Diabetes Research Foundation, Finland, Finnish Foundation for Cardiovascular Research, Juho Vainio Foundation |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Insulin sensitivity | Change in insulin sensitivity measured by oral glucose tolerance test at baseline and after 6 months | Six months | No |
Secondary | Peripheral blood mononuclear cell gene expression | Six months | No | |
Secondary | Inflammation | Change in inflammation measured as serum cytokines and adipose tissue inflammation at baseline and after 6 months | Baseline to six months | No |
Secondary | Adipose tissue gene expression | Six months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02829229 -
Community-based Obesity Treatment in African American Women After Childbirth
|
N/A |